三种挽救化疗方案对初始诱导失败/复发AML患者的疗效及安全性分析  

Efficacy and Safety of Three Salvage Chemotherapy Regimens for Patients with Refractory/Relapsed Acute Myeloid Leukemia

作　　者：王慧[1] 刘晓娟[1] 毋艳[1] WANG Hui;LIU Xiao-juan;WU Yan(Jiaozuo Second People's Hospital ,Jiaozuo 454001,China)

机构地区：[1]焦作市第二人民医院

出　　处：《肿瘤学杂志》2018年第12期1196-1200,共5页Journal of Chinese Oncology

摘　　要：[目的]探讨FLAG、CAG及MAC方案对初始诱导失败/复发AML患者疾病缓解率、生存时间及毒副作用的影响。[方法] 150例诱导失败/复发AML患者,根据治疗方案不同分为FLAG组(50例)、CAG组(50例)及MAC组(50例),比较三组患者疾病缓解率、中位无进展生存时间、中位总生存时间及毒副作用发生率。[结果] MAC组患者完全缓解率高于FLAG、CAG组(P<0.05);三组患者部分缓解率比较差异无统计学意义(P>0.05);MAC组患者总体反应率显著高于FLAG组(P<0.05)。三组患者中位无进展生存时间比较差异无统计学意义(P>0.05);MAC组患者中位总生存时间长于FLAG、CAG组(P<0.05)。三组患者肝功能损伤、肾功能损伤、腹泻及恶心呕吐发生率比较差异均无统计学意义(P>0.05);CAG、MAC组患者Ⅰ~Ⅱ度继发感染发生率均显著高于FLAG组(P<0.05);但三组患者Ⅲ~Ⅳ度继发感染发生率比较差异无统计学意义(P>0.05)。[结论]相较于FLAG和CAG方案,MAC方案治疗初始诱导失败/复发AML可有效提高疾病缓解率,延长总生存时间,且未增加严重毒副作用发生风险。[Objective] To assess the efficacy and safety of FLAG,CAG and MAC regimens in treatment of patients with refractory/relapsed acute myeloid leukemia(AML). [Methods] One hundred and fifty patients with refractory/relapsed AML were enrolled and randomly assigned to receive FLAG,CAG or MAC regimens for salvage chemotherapy with 50 cases in each group. And the disease remission,the median progression-free survival(PFS),the median overall survival(OS) and the incidence of adverse effects in three groups were compared. [Results] The complete remission rate of MAC group were significant higher than that in FLAG group and CAG group(P<0.05). There was no significant difference in the partial remission rate among three groups(P>0.05). The overall response rate in MAC group was significant higher than that in FLAG group(P<0.05). There was no significant difference in the median PFS among three groups(P>0.05). The median OS in MAC group were significant longer than that in FLAG group and CAG group(P<0.05). There was no significant difference in the incidence of liver dysfunction,renal dysfunction,diarrhea and vomit among three groups(P>0.05). The incidence of Ⅰ~Ⅱ degree infection in CAG group and MAC group was significant higher than that in FLAG group(P<0.05). There was no significant difference in the incidence of Ⅲ~Ⅳ degree infection among three groups(P>0.05). [Conclusion] Compared with FLAG and CAG regimen,MAC regimen can efficiently improve the disease remission prolong the survival time without increasing risk of serious adverse reactions in treatment of patients with refractory/relapsed AML.

关 键 词：FLAG CAG MAC 挽救化疗 急性髓系白血病 

分 类 号：R733.7[医药卫生—肿瘤]